EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2017 Sep 6

PMID 28872581

Citations 99

Authors

Sarah R Sabir

Sharon Yeoh

George Jackson

Richard Bayliss

Affiliations

Soon will be listed here.

Abstract

Since the discovery of the fusion between EML4 (echinoderm microtubule associated protein-like 4) and ALK (anaplastic lymphoma kinase), EML4-ALK, in lung adenocarcinomas in 2007, and the subsequent identification of at least 15 different variants in lung cancers, there has been a revolution in molecular-targeted therapy that has transformed the outlook for these patients. Our recent focus has been on understanding how and why the expression of particular variants can affect biological and molecular properties of cancer cells, as well as identifying the key signalling pathways triggered, as a result. In the clinical setting, this understanding led to the discovery that the type of variant influences the response of patients to ALK therapy. Here, we discuss what we know so far about the EML4-ALK variants in molecular signalling pathways and what questions remain to be answered. In the longer term, this analysis may uncover ways to specifically treat patients for a better outcome.

Citing Articles

Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer.

Sampson J, Ju H, Zhang N, Yeoh S, Choi J, Bayliss R Cell Death Dis. 2024; 15(12):912.

PMID: 39695132 PMC: 11655848. DOI: 10.1038/s41419-024-07272-7.

Microtubule Association of EML4-ALK V3 Is Key for the Elongated Cell Morphology and Enhanced Migration Observed in V3 Cells.

Papageorgiou S, Pashley S, ORegan L, Straatman K, Fry A Cells. 2024; 13(23).

PMID: 39682703 PMC: 11639804. DOI: 10.3390/cells13231954.

Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study.

Kamali C, Tsakonas G, Hydbring P, Jatta K, Berglund A, Viktorsson K Transl Lung Cancer Res. 2024; 13(11):2918-2933.

PMID: 39670024 PMC: 11632442. DOI: 10.21037/tlcr-24-396.

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.

Gonzalez-Martinez D, Roth L, Mumford T, Guan J, Le A, Doebele R Nat Commun. 2024; 15(1):9473.

PMID: 39488530 PMC: 11531495. DOI: 10.1038/s41467-024-53451-7.

Liquid-liquid phase separation: a new perspective on respiratory diseases.

Wang L, Wang Y, Ke Z, Wang Z, Guo Y, Zhang Y Front Immunol. 2024; 15:1444253.

PMID: 39391315 PMC: 11464301. DOI: 10.3389/fimmu.2024.1444253.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Camidge D, Bang Y, Kwak E, Iafrate A, Varella-Garcia M, Fox S . Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13(10):1011-9. PMC: 3936578. DOI: 10.1016/S1470-2045(12)70344-3. View

Soda M, Takada S, Takeuchi K, Choi Y, Enomoto M, Ueno T . A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008; 105(50):19893-7. PMC: 2605003. DOI: 10.1073/pnas.0805381105. View

Thun M, DeLancey J, Center M, Jemal A, Ward E . The global burden of cancer: priorities for prevention. Carcinogenesis. 2009; 31(1):100-10. PMC: 2802672. DOI: 10.1093/carcin/bgp263. View

Heidebrecht H, Buck F, Pollmann M, Siebert R, Parwaresch R . Cloning and localization of C2orf2(ropp120), a previously unknown WD repeat protein. Genomics. 2000; 68(3):348-50. DOI: 10.1006/geno.2000.6301. View

Morris S, Kirstein M, Valentine M, Dittmer K, Shapiro D, Saltman D . Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263(5151):1281-4. DOI: 10.1126/science.8122112. View

Suprenant K, Dean K, McKee J, Hake S . EMAP, an echinoderm microtubule-associated protein found in microtubule-ribosome complexes. J Cell Sci. 1993; 104(2):445-50. DOI: 10.1242/jcs.104.2.445. View

Solomon B, Mok T, Kim D, Wu Y, Nakagawa K, Mekhail T . First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77. DOI: 10.1056/NEJMoa1408440. View

Cha Y, Kim H, Shim H . Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants. J Transl Med. 2016; 14(1):296. PMC: 5069800. DOI: 10.1186/s12967-016-1061-z. View

10.

Bulinski J, Borisy G . Self-assembly of microtubules in extracts of cultured HeLa cells and the identification of HeLa microtubule-associated proteins. Proc Natl Acad Sci U S A. 1979; 76(1):293-7. PMC: 382925. DOI: 10.1073/pnas.76.1.293. View

11.

Sanders H, Li H, Bruey J, Scheerle J, Meloni-Ehrig A, Kelly J . Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet. 2011; 204(1):45-52. DOI: 10.1016/j.cancergencyto.2010.08.024. View

12.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

13.

Choi Y, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T . EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363(18):1734-9. DOI: 10.1056/NEJMoa1007478. View

14.

Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H . Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(28):3383-9. DOI: 10.1200/JCO.2015.65.8732. View

15.

Liu J, Ma S . Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer. Curr Med Chem. 2016; 24(6):590-613. DOI: 10.2174/0929867323666161029223823. View

16.

Sasaki T, Rodig S, Chirieac L, Janne P . The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46(10):1773-80. PMC: 2888755. DOI: 10.1016/j.ejca.2010.04.002. View

17.

Costa D, Shaw A, Ou S, Solomon B, Riely G, Ahn M . Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015; 33(17):1881-8. PMC: 4451171. DOI: 10.1200/JCO.2014.59.0539. View

18.

Hanna N, Shepherd F, Fossella F, Pereira J, de Marinis F, von Pawel J . Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22(9):1589-97. DOI: 10.1200/JCO.2004.08.163. View

19.

Lei Y, Yang J, Zhang X, Zhong W, Zhou Q, Tu H . Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. Clin Lung Cancer. 2015; 17(3):223-31. DOI: 10.1016/j.cllc.2015.09.002. View

20.

Suprenant K, Tuxhorn J, Daggett M, Ahrens D, Hostetler A, Palange J . Conservation of the WD-repeat, microtubule-binding protein, EMAP, in sea urchins, humans, and the nematode C. elegans. Dev Genes Evol. 1999; 210(1):2-10. DOI: 10.1007/pl00008183. View